QR Pharma Announces New Scientific Advisory Board with Appointment of World-Class Neurodegenerative Disease Experts

Four Neurology Experts Join Advisory Board Following Recent Breakthrough Discoveries Regarding Posiphen Mechanism of Action

Berwyn, PA, January 24, 2017 — QR Pharma, Inc., a privately held Phase 2 biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, today announced the appointment of four world-class key opinion leaders to  its Scientific Advisory Board (SAB). These new appointments join QR Pharma’s previous roster of impressive advisors in order to provide strategic leadership and direction to support the development of the breakthrough mechanism of action of Posiphen in neurodegenerative disease.

 

Posiphen is a first-in-class inhibitor of the neurotoxic aggregating proteins involved in the pathogenesis of conditions such as Alzheimer’s and Parkinson’s disease. Posiphen has been shown to reduce the expression of key neurodegenerative proteins including amyloid precursor protein, alpha synuclein and tau. This innovative mechanism of action could be applicable to several conditions in which multiple neurodegenerative proteins share responsibility for disease pathogenesis. Posiphen is currently being evaluated in a Phase 2A proof-of-concept/mechanism study for patients with early Alzheimer’s disease.

 

“We are thrilled to have attracted four world-class experts in the area of neurology to our team of scientific advisors,” stated Maria Maccecchini, Ph.D., President and CEO of QR Pharma.  “They join at an exciting time for our company.  Recent breakthrough discoveries regarding Posiphen’s mechanism of action suggest a first-in-class disease-modifying therapeutic with broad clinical application.  The experience each of the new advisors brings to our team will be invaluable in realizing the full therapeutic potential of Posiphen in neurodegenerative disease.”

 

“Posiphen represents an opportunity to attack neurodegenerative disease at its roots,” commented Dr. Sidney Strickland, new Chairman of the QR Pharma SAB and Professor of Neurology and Genetics at Rockefeller University. “Unlike other therapeutic modalities that only attack a single axis of neurodegenerative disease pathogenesis, Posiphen targets multiple disease-causing proteins.  I look forward to working with the fellow members of the SAB and QR Pharma leadership to advance this promising therapeutic agent for patients suffering from debilitating neurodegenerative conditions.”

 

The four new scientific advisory board members are:

 

  • William Mobley, M.D., Ph.D., is Distinguished Professor, Department of Neurosciences Florence Riford Chair for Alzheimer Research and Associate Dean for Neurosciences Initiatives. He is a member of the National Academy of Medicine. His research focuses on the neurobiology of neurotrophic factor actions/signaling and on the hypothesis that dysfunction of such signaling mechanisms contribute to neuronal dysfunction in developmental and age-related disorders of the neurosystem.

 

 

  • Sidney Strickland, Ph.D., is the Vice President and Dean for Educational Affairs and Research Professor, Patricia and John Rosenwald Laboratory of Neurobiology and Genetics at Rockefeller University. Dr. Strickland’s laboratory investigates how dysfunction of the circulatory system contributes to Alzheimer’s and other neurodegenerative disorders.  He will serve as the Chairman of QR Pharma’s SAB.

 

  • Rudolph Tanzi, Ph.D., is Vice-Chair and Director of Neurology, Genetics and Aging, and the Joseph and Rose Kennedy Professor of Neurology at Massachusetts General Hospital. Tanzi investigates the molecular and genetic basis of neurological disease and discovered the location of the Huntington’s disease gene. He co-discovered all three genes that cause early-onset familial Alzheimer’s disease, including the first familial Alzheimer’s disease gene, known as the amyloid β-protein (A4) precursor (APP), and the presenilin genes.

 

These new advisory board members join Dr. Jeff Cummings and Dr. Peter Davies, who already serve on the advisory board:

 

  • Jeffrey Cummings, MD, Cleveland Clinic, is Director, Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada and Cleveland, Ohio. Camille and Larry Ruvo Chair of the Neurological Institute of Cleveland Clinic and Professor of Medicine (Neurology), Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.  Dr. Cummings is a world-renowned Alzheimer’s clinical researcher interested in novel therapies for brain diseases.
  • Cummings is a world-renowned Alzheimer’sresearcher and leader of clinical trials. He has been recognized for his research and leadership contributions inthe field of Alzheimer’s disease through the Henderson Award of the AmericanGeriatrics Society (2006), the Research Award of the John Douglas FrenchAlzheimer’s Research Foundation (2008), and the Ronald and Nancy ReaganResearch Award of the national Alzheimer’s Association (2008). In 2010, he washonored by the American Association of Geriatric Psychiatry with theirDistinguished Scientist Award. In 2011,he was awarded a Doctor of Science by his Alma mater, University of Wyoming. He was featured in the Gentleman’s Quarterly(June 2009) as a “Rockstar of Science.”
  • Cummings is interested in clinical trials,developing new therapies for brain diseases, and the interface of neuroscienceand society.
  • Cummings is a world-renowned Alzheimer’sresearcher and leader of clinical trials. He has been recognized for his research and leadership contributions inthe field of Alzheimer’s disease through the Henderson Award of the AmericanGeriatrics Society (2006), the Research Award of the John Douglas FrenchAlzheimer’s Research Foundation (2008), and the Ronald and Nancy ReaganResearch Award of the national Alzheimer’s Association (2008). In 2010, he washonored by the American Association of Geriatric Psychiatry with theirDistinguished Scientist Award. In 2011,he was awarded a Doctor of Science by his Alma mater, University of Wyoming. He was featured in the Gentleman’s Quarterly(June 2009) as a “Rockstar of Science.”
  • Cummings is interested in clinical trials,developing new therapies for brain diseases, and the interface of neuroscienceand society.
  • Cummings is a world-renowned Alzheimer’sresearcher and leader of clinical trials. He has been recognized for his research and leadership contributions inthe field of Alzheimer’s disease through the Henderson Award of the AmericanGeriatrics Society (2006), the Research Award of the John Douglas FrenchAlzheimer’s Research Foundation (2008), and the Ronald and Nancy ReaganResearch Award of the national Alzheimer’s Association (2008). In 2010, he washonored by the American Association of Geriatric Psychiatry with theirDistinguished Scientist Award. In 2011,he was awarded a Doctor of Science by his Alma mater, University of Wyoming. He was featured in the Gentleman’s Quarterly(June 2009) as a “Rockstar of Science.”
  • Cummings is interested in clinical trials,developing new therapies for brain diseases, and the interface of neuroscienceand society.

 

  • Peter Davies, PhD, is Director of the Litwin-Zucker Research Center for the Study of Alzheimer’s Disease, The Feinstein Institute for Medical Research and Professor, Pathology and Neuroscience, at the Hofstra Northwell School of Medicine at Hofstra University. Davies’ research is focused on improving the understanding of Alzheimer’s disease to allow for the discovery, development and testing of effective therapies.

 

About QR Pharma, Inc.

Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of neurological disorders.

QR is currently developing Posiphen as a disease-modifying drug for acute as well as chronic neurodegeneration and bisnorcymserine (BNC) for advanced Alzheimer’s disease. For more information on QR Pharma, please visit the company’s website, www.qrpharma.com

Contact: Maria Maccecchini
Tel: 610-727 3710
Fax: 610 727 4001
maccecchini@qrpharma.com
www.qrpharma.com

QR Pharma Raises $800,000 of Series A Preferred Stock

Berwyn, PA., October 27, 2016 — QR Pharma, Inc., a privately held biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, has closed on $800,000 of Series A Preferred Stock financing. Existing investors Robin Hood Ventures and individual angels filled this round.

QR Pharma will use the funding to continue to develop its lead compound, Posiphen®, build a pipeline and to support the company through the end of a phase II clinical study in Alzheimer patients. “This financing together with $2M from the NIH provides QR with adequate means to test Posiphen for efficacy in a human phase II study conducted by ADCS,” said QR President and CEO Maria Maccecchini, PhD.

The drug QR is developing represents a new approach to the treatment of neurodegenerative diseases. Posiphen is neuroprotective. By inhibiting the synthesis of neurotoxic aggregating proteins it protects nerve cells from these toxic proteins and prevents them from dying.

About QR Pharma: Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches to the treatment of cognitive impairment in neurological disorders. QR has successfully completed animal studies in Alzheimer’s and Parkinson’s disease models; is expanding the drugs application to Huntington’s, glaucoma and traumatic brain injury, was awarded $3 M from the US Army to work in Traumatic Brain Injury (TBI); and has recently been chosen by the NIH for a human phase 2 clinical trial in Alzheimer’s patients.
For more information on QR Pharma, please visit the company’s website, http://www.qrpharma.com/.

 

Contact: Maria L. Maccecchini, CEO
Tel: 610 727 3710
maccecchini@qrpharma.com
www.qrpharma.com

QR Pharma, Inc. to Participate in Harvard’s Neuro Advance Boston Conference

–President and CEO, Dr. Maria Maccecchini, to Speak in Panel–

 

Berwyn, Pa., October 4, 2016 — QR Pharma, Inc., a privately held Phase 2 biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, today announced that Maria Maccecchini, Ph.D., President and CEO, will participate in the Neuro Advance Boston Conference being held on October 5, 2016 at Harvard Medical School in Boston, MA.

 

Dr. Maria Maccecchini will be a speaker in a panel entitled “2017 Market Outlook: Alternative Sources of Funding.” Neuro Advance Boston is an off-the-record forum that brings together Heads from top biopharmaceutical companies, CEOs, CMOs, and CSOs  working in the neuroscience and pain management space to discuss the critical issues facing neuro drug development.

 

About QR Pharma, Inc.

Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment in neurological disorders.

QR is currently developing Posiphen as a disease-modifying drug for acute as well as chronic neurodegeneration and BNC for advanced Alzheimer’s disease. For more information on QR Pharma, please visit the company’s website, www.qrpharma.com

Contact: Maria Maccecchini
Tel: 610-727 3710
Fax: 610 727 4001
maccecchini@qrpharma.com
www.qrpharma.com

Presentation at NewsMakers

QR Pharma, Inc. to Present Corporate Update at 23rd Annual

BioCentury NewsMakers Conference

 

–One of Fourteen Private Companies Selected to Present–

 

Berwyn, PA, September 9, 2016 — QR Pharma, Inc., a privately held Phase 2 biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, today announced that Maria Maccecchini, Ph.D., President and CEO, will present a corporate update at the 23rd Annual BioCentury NewsMakers in the Biotech Industry Conference at 3:00 PM ET on September 9, 2016 at the Millennium Broadway Hotel & Conference Center in New York, NY.    Dr. Maccecchini will also be participating in 1×1 meetings with investors and industry executives.

 

About QR Pharma, Inc.

Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment in neurological disorders.

QR is currently developing Posiphen as a disease-modifying drug for acute as well as chronic neurodegeneration and BNC for advanced Alzheimer’s disease. For more information on QR Pharma, please visit the company’s website, www.qrpharma.com

Contact: Maria Maccecchini
Tel: 610-727 3710
Fax: 610 727 4001
maccecchini@qrpharma.com
www.qrpharma.com

New Data on Posiphen in Traumatic Brain Injury

QR Pharma, Inc. Presents New Data on Posiphen in Traumatic Brain Injury at

2016 Military Health System Research Symposium

–Posiphen Reverses Behavioral Deficits and Neuropathology Caused by Traumatic Brain Injury–

Berwyn, Pa., August 17, 2016 — QR Pharma, Inc., a privately held Phase 2 biopharmaceutical company

developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative

diseases, today announced the presentation of non-clinical data relating to its lead clinical product candidate,

Posiphen, at the 2016 Military Health System Research Symposium (MHSRS) being held August 15 – 18 in

Orlando, Florida.

The presentation highlighted studies conducted by investigators from The David Geffen School of Medicine at

UCLA characterizing the effects of Posiphen in a non-clinical model of traumatic brain injury (TBI). These

blinded studies revealed that Posiphen (2.5, 5 and 10 mg/kg) administered daily attenuated spatial working

memory deficits while also rescuing tissue damage, normalizing inflammation and reversing the molecular

pathology caused by TBI.

“These are impressive results for Posiphen in a high-fidelity rodent model of TBI,” commented Marie-Françoise

Chesselet, M.D., Ph.D., Professor and Interim Chair of the Department of Neurology at UCLA and principle

investigator for the studies. “Posiphen completely rescues working memory and consistently improves cell

function and survival in the substantia nigra and striatum, regions of the brain that are often damaged following

repeated TBI leading to the onset of Parkinson’s disease.”

“These studies provide further confirmation of the neuroprotective effects of Posiphen,” stated Maria

Maccecchini, Ph.D., President and CEO of QR Pharma. “These results add to a deep data set supporting the

unique activity and potentially broad application of Posiphen in TBI and other neurodegenerative conditions,

such as Parkinson’s and Alzheimer’s.”

A full copy of the MHSRS poster entitled, “Posiphen reverses behavioral deficits and neuropathology in a rat

model of mild traumatic brain injury,” can be accessed by visiting the “Scientific Presentations” in the Press

Room section of QR Pharma’s website at www.qrpharma.com.

About QR Pharma, Inc.

Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical

company committed to developing therapeutics with novel approaches for the treatment of cognitive

impairment in neurological disorders.

QR is currently developing Posiphen as a disease-modifying drug for acute as well as chronic

neurodegeneration and BNC for advanced Alzheimer’s disease. For more information on QR Pharma, please

visit the company’s website, www.qrpharma.com

Contact: Maria Maccecchini

Tel: 610-727 3710

Fax: 610 727 4001

maccecchini@qrpharma.com

www.qrpharma.com

 

Posiphen poster MHSRS

QR Pharma to Present a Paper on Clinical Development of its Lead Compound, Posiphen, in Alzheimer’s Disease

Berwyn, Pennsylvania, November 2, 2015 – Maria Maccecchini, PhD, President and CEO of QR Pharma, Inc. is presenting a paper entitled “Analysis of Multiple Biomarkers and Factors in Blood and CSF in Phase 2 to Facilitate Choice of End Points in Phase 3” is part of a Forum on CNS Clinical Trials. The presentation is focused on the difficulties associated with clinical trials in Alzheimer’s disease and proposes a strategy to optimize development of its lead compound, Posiphen®.

The Forum addresses the slowing of drug approval, the exorbitant failure rate in CNS clinical trials and how to position CNS drugs for success. The event runs from November 2 to 3, 2015, in Bethesda, MD, and Dr. Maccecchini’s talk is on Monday, November 2, 2015 at 11:45 AM.

About QR Pharma, Inc.

Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment in neurological disorders.

QR is currently developing Posiphen as a disease-modifying drug for acute as well as chronic neurodegeneration and BNC for advanced Alzheimer’s disease. For more information on QR Pharma, please visit the company’s website, www.qrpharma.com

Contact: Maria Maccecchini
Tel: 610-727 3710
Fax: 610 727 4001
maccecchini@qrpharma.com
www.qrpharma.com

QR Pharma Issues $5.7 M of Series A Preferred Stock

Maria Maccecchini, President and CEO of QR Pharma, Inc. to Serve on Panel with Nobel Laureate, Phillip Sharp at Chemical Heritage Foundation Event

Berwyn, Pennsylvania, May 11, 2015 – Maria Maccecchini, PhD, President and CEO of QR Pharma, Inc. and Philip A. Sharp will be discussing “Secrets of a Science: Challenges and Opportunities of Biomedical Research”. The conversation will span the progress of Science from its beginnings into the future. The event is part of a Heritage Day celebration being held by the Chemical Heritage Foundation on May 14, 2015.\

Dr. Maccecchini will converse with this year’s Othmer Gold Medal recipient Dr. Phillip Sharp, Professor, Massachusetts Institute of Technology. The Othmer Gold Medal will be awarded to Dr. Sharp by the Chemical Heritage Foundation in recognition of his outstanding activity in such areas as innovation, entrepreneurship, research, education in the field of Chemistry.

Dr. Sharp is also the recipient of the 1993 Nobel Prize in Physiology or Medicine for his landmark work in the mechanisms of RNA splicing.
About QR Pharma, Inc.

Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment in neurological disorders.

QR is currently developing Posiphen as a disease modifying drug for acute as well as chronic neurodegeneration and BNC for advanced Alzheimer’s disease. For more information on QR Pharma, please visit the company’s website, www.qrpharma.com

Contact: Contact: Maria L. Maccecchini, CEO
Tel: 610 727 3710
Fax: 610 727 4001
maccecchini@qrpharma.com
www.qrpharma.com

Peter Davies, the 2015 Recipient of the Potamkin Award, Joins the Scientific Advisory Board of QR Pharma

QR Pharma Receives US Patent 8,691,864 to Treat Dementia